Provided by Tiger Trade Technology Pte. Ltd.

Altimmune, Inc.

4.01
+0.12603.25%
Volume:1.05M
Turnover:4.16M
Market Cap:521.06M
PE:-4.01
High:4.04
Open:3.90
Low:3.87
Close:3.88
52wk High:7.73
52wk Low:2.90
Shares:130.07M
Float Shares:124.00M
Volume Ratio:0.88
T/O Rate:0.85%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9999
EPS(LYR):-0.9999
ROE:-50.57%
ROA:-28.17%
PB:2.32
PE(LYR):-4.01

Loading ...

Press Release: Altimmune Announces CEO Transition and Succession Plan

Dow Jones
·
Dec 01, 2025

FACTBOX-Weight-loss drug developers line up to tap lucrative market as competition heats up

Reuters
·
Nov 25, 2025

Altimmune Inc Files For Mixed Shelf Of Up To $400 Million - SEC Filing

Reuters
·
Nov 20, 2025

Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing

Reuters
·
Nov 20, 2025

TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies

GlobeNewswire
·
Nov 19, 2025

2025 Ergothioneine Brand Comprehensive Evaluation Research Report: In-depth Analysis of Seven Popular Brands Based on Ingredient Efficacy, Technological Barriers, and Market Landscape

Deep News
·
Nov 18, 2025

Altimmune Inc. Publishes Results of Phase 2b Trial of Pemvidutide in MASH

Reuters
·
Nov 11, 2025

Altimmune announces publication of IMPACT Phase 2b trial data

TIPRANKS
·
Nov 11, 2025

Altimmune Announces Publication of Impact Phase 2B Trial Data in the Lancet and Concurrent Late-Breaking Oral Presentation at Aasld the Liver Meeting® 2025

THOMSON REUTERS
·
Nov 11, 2025

Analysts Are Bullish on These Healthcare Stocks: Altimmune (ALT), Dogwood Therapeutics (DWTX)

TIPRANKS
·
Nov 08, 2025

Altimmune Is Maintained at Market Outperform by Citizens

Dow Jones
·
Nov 07, 2025

Altimmune announce results from analysis of biopsies from IMPACT Phase 2b trial

TIPRANKS
·
Nov 07, 2025

Immunocore presents Phase 1 data for hepatitis B candidate at AASLD’s The Liver Meeting

GlobeNewswire
·
Nov 07, 2025

BRIEF-Altimmune Files For Offering Of Common Stock Of Up To $200 Million - Filing

Reuters
·
Nov 07, 2025

Altimmune Inc Files for Mixed Shelf of up to $400 Mln - SEC Filing

THOMSON REUTERS
·
Nov 07, 2025

Altimmune: Files for Offering of Common Stock of up to $200 Mln - Filing

THOMSON REUTERS
·
Nov 07, 2025

BRIEF-Altimmune Amends Loan And Security Agreement With Hercules Capital - SEC Filing

Reuters
·
Nov 06, 2025

Altimmune Inc - Amends Loan and Security Agreement With Hercules Capital - SEC Filing

THOMSON REUTERS
·
Nov 06, 2025

Altimmune Inc - Term Loan Increased From $100 Mln to $125 Mln - SEC Filing

THOMSON REUTERS
·
Nov 06, 2025

Altimmune Q3 revenue beats expectations

Reuters
·
Nov 06, 2025